CTS position statement: Pharmacotherapy in patients with COPD—An update

Abstract

RATIONALE: Since the last published Canadian Thoracic Society (CTS) COPD guideline in 2007 and the 2008 update -highlights for primary care, many new clinical trials have challenged COPD treatment practices. The current Canadian position statement provides the reader with an update on pharmacotherapy of patients with COPD as reviewed by the CTS. OBJECTIVES: The objectives of this position statement are: 1) to summarize the literature on topics relevant to the pharmacological therapy of patients with stable COPD; and 2) to provide clinical guidance with evidence-based recommendations and expert-informed key messages for the pharmacological therapy for patients with stable COPD. METHODS: The authors systematically reviewed the relevant literature focusing on randomized controlled trials and when available, systematic reviews of randomized controlled trials. The proposed key messages, based on scientific evidence and expert-informed opinion, were agreed upon by a majority consensus. MAIN RESULTS: There is typically a significant delay in seeking medical care by patients with dyspnea, often waiting until symptoms affect the performance of activities of daily living. The diagnosis of COPD requires spirometry to confirm the presence of airflow obstruction in any patient presenting with symptoms and/or risk factors of COPD. An effective management plan for individuals with COPD should include: smoking cessation, vaccination and education. A number of non-pharmacological treatments are available for COPD patients with symptoms to improve outcomes such as self-management with coaching from a health care professional; pulmonary rehabilitation; supplemental oxygen in selected patients; and surgery.Current pharmacotherapy for COPD has been shown to alleviate symptoms and prevent exacerbations and related complications such as hospital admissions. In symptomatic patients with stable COPD not having or having infrequent exacerbation, treatment should be started with inhaled LAMA or LABA monotherapy, and if experiencing persistent or increased dyspnea, exercise intolerance, and/or reduced health status despite use of monotherapy, patients should be considered for treatment "step up" with an inhaled LAMA plus LABA dual therapy. In this situation, the use of a single inhaler would be preferred to simplify the treatment regimen and minimize the cost. In patients with stable COPD experiencing exacerbations despite the use of LAMA or LABA monotherapy, treatment "step up" with inhaled LAMA plus LABA dual therapy should be considered unless a patient has concomitant asthma (Asthma/COPD overlap (ACO)). There has been recent interest in using biomarkers to identify patients who are more likely to respond to ICS. Most of the studies have demonstrated that high blood eosinophils could be valuable to predict an increase response in terms of reduction of exacerbation rate when treated with combination ICS/LABA; there is still uncertainty about the exact cut-off level of blood eosinophils having potential therapeutic value. If a pa...

Can Patients With COPD Assimilate Disease-Specific Information During an Acute Exacerbation?

“…This highlights the need for an improved understanding of prescribed medications which may be of pharmacologic benefit in preventing and controlling exacerbations. 25 The majority of the questions in the LINQ ask whether or not a doctor or nurse has explained a specific question to the patient. Since a physiotherapist delivered the program, had the wording been altered to include physiotherapists or a more general term for healthcare professionals, we may have seen a change in these results.…”

Inhaled corticosteroids preventing pneumonia mortality: paradox or selection bias?

“…However, the observational studies conducted among patients hospitalised for pneumonia reporting that prior ICS use is associated with decreased mortality obscure this evidence. This paradox of ICS appearing to increase pneumonia incidence but to lower post-pneumonia mortality has puzzled clinicians and scientists, even creating uncertainty in recommendations on the safety of ICS by COPD treatment guideline committees [16][17][18].…”

“…It would instead be applicable to a study of the incidence of pneumonia-related mortality. This paradox also introduced some uncertainty for treatment guideline recommendations on the use and safety of ICS in treating COPD [18].…”

Tiotropium (SPIRIVA®) in mild COPD: Is it worth it?

“…Symptoms of COPD usually manifests after the age of 40, which explains the lack of data in younger individuals 4 . Based on the 2017 Canadian Thoracic Society (CTS) position statement, Modified Medical Research Council (mMRC) and COPD Assessment Test (CAT) symptom scores along with the frequency and severity of acute exacerbations of COPD (AECOPD) are used to classify COPD patients as mild, moderate and severe 5 .…”